Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’

Start-Up Raises $17.5m In Series A

Executive Summary

Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.

You may also be interested in...



Interview: Achilles Advances Armed With £100m

After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.

First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives

A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.

Moderna Expands Horizons With Vertex and Chiesi Deals

The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel